Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141790

Published: 2020

Journal Articles

Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy

Radovan Vasic, MD MHS, Yuliang Shi, Andrea Arruda, MSc, Sarah Malik, Jaime Claudio, PhD, Jose-Mario Capo-Chichi, PhD, Aniket Bankar, MBBS, MD DM, Hassan Sibai, MBBS, Dawn Maze, MDFRCPC,MSc, James A. Kennedy, MDPhD, Wei Xu, PhD, Vikas Gupta, MD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-139936

Published: 2020

Journal Articles

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

Blood (2017) 130 (Supplement 1): 788.

https://doi.org/10.1182/blood.V130.Suppl_1.788.788

Published: 2017

Journal Articles

Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML.

Richard Ward, BSc, MRCP, FRCPath, Vikas Gupta, MD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Karen WL Yee, MD, Andre Schuh, MD, Wei Xu, PhD, Joseph Brandwein, MD

Blood (2009) 114 (22): 1036.

https://doi.org/10.1182/blood.V114.22.1036.1036

Published: 2009

Journal Articles

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Donna E. Reece, MD, Young Trieu, MSc, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD

Blood (2009) 114 (22): 1853.

https://doi.org/10.1182/blood.V114.22.1853.1853

Published: 2009

Journal Articles

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Gloria Lim, BSc, MSc, MD, Wei Xu, PhD, Trieu Young, MSc, Andrew Winter, BScN, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 2154.

https://doi.org/10.1182/blood.V114.22.2154.2154

Published: 2009

Journal Articles

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Richard Ward, BSc, MRCP, FRCPath, Suzanne Kamel-Reid, PhD, FACMG, Wei Xu, PhD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Karen WL Yee, MD, Andre Schuh, MD, Vikas Gupta, MD, Joseph Brandwein, MD

Blood (2009) 114 (22): 1591.

https://doi.org/10.1182/blood.V114.22.1591.1591

Published: 2009

Journal Articles

Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

Trieu Young, MSc, Chia-Min Chu, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD, Donna E. Reece, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC

Blood (2009) 114 (22): 3855.

https://doi.org/10.1182/blood.V114.22.3855.3855

Published: 2009

Journal Articles

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.

Hong Chang, Young Trieu, MSc, Connie Qi, Wei Xu, PhD, Donna E. Reece

Blood (2009) 114 (22): 2826.

https://doi.org/10.1182/blood.V114.22.2826.2826

Published: 2009

Journal Articles

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Christine Chen, MD, Young Trieu, MSc, Wei Xu, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Donna E. Reece, MD

Blood (2009) 114 (22): 3345.

https://doi.org/10.1182/blood.V114.22.3345.3345

Published: 2009

Journal Articles

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Carla Borgono, MSc, PhD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 3409.

https://doi.org/10.1182/blood.V114.22.3409.3409

Published: 2009

Journal Articles

A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Christine Chen, MD, Harminder Paul, Wei Xu, PhD, Vishal Kukreti, Suzanne Trudel, Ellen Wei, Zhi Hua Li, Joseph Brandwein, Mariela Pantoja, Chungyee Leung-Hagensteijn

Blood (2008) 112 (11): 44.

https://doi.org/10.1182/blood.V112.11.44.44

Published: 2008

Journal Articles

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Susan Kao, MD, Wei Xu, PhD, Vikas Gupta, MD, MRCP, MRCPath, Mark Minden, Andre Schuh, MD, Aaron D. Schimmer, Karen WL Yee, Joseph Brandwein, MD, FRCPC

Blood (2008) 112 (11): 3962.

https://doi.org/10.1182/blood.V112.11.3962.3962

Published: 2008

Journal Articles

Genetic Variants in the Candidate Genes of the Apoptosis Pathway and Susceptibility to Chronic Myeloid Leukemia

Dong Hwan Kim, MD, PhD, Kyoung Ha Kim, M.D., Myung Hee Chang, M.D., Wei Xu, PhD, Clement Ma, MSc, Xiangdong Liu, Ph.D., Katherine Siminovitch, M.D./Ph.D., Hans A. Messner, M.D./Ph.D, Jeffrey H. Lipton, MD, PhD

Blood (2008) 112 (11): 4223.

https://doi.org/10.1182/blood.V112.11.4223.4223

Published: 2008

Journal Articles

Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy.

Dong Hwan Kim, MD, PhD, Hee Kyung Ahn, M.D., Wei Xu, PhD, Suzanne Kamel-Reid, PhD, FACMG, Xiangdong Liu, Ph.D., Katherine Siminovitch, M.D./Ph.D., Jeffrey H. Lipton, MD, PhD

Blood (2008) 112 (11): 1110.

https://doi.org/10.1182/blood.V112.11.1110.1110

Published: 2008

Journal Articles

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Anca Prica, MD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2008) 112 (11): 3315.

https://doi.org/10.1182/blood.V112.11.3315.3315

Published: 2008

Journal Articles

Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.

Young Trieu, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Donna E. Reece, MD

Blood (2008) 112 (11): 3323.

https://doi.org/10.1182/blood.V112.11.3323.3323

Published: 2008

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

Donna E. Reece, MD, Young Trieu, MSc, Hong Chang, MD, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Joseph Mikhael, MD

Blood (2008) 112 (11): 1724.

https://doi.org/10.1182/blood.V112.11.1724.1724

Published: 2008

Journal Articles

Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Hong Chang, MD, Connie Qi, MD, Allan Jiang, Wei Xu, PhD, Young Trieu, MSc, Donna E. Reece, MD

Blood (2008) 112 (11): 1702.

https://doi.org/10.1182/blood.V112.11.1702.1702

Published: 2008

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Carla Borgono, PhD, Young Trieu, MSc, Wei Xu, PhD, Jacob Pendergrast, MD, Donna Reece, MD, Suzanne Trudel, MD, Joseph Mikhael, MD, Vishal Kukreti, MD, Christine I. Chen, MD

Blood (2007) 110 (11): 4952.

https://doi.org/10.1182/blood.V110.11.4952.4952

Published: 2007

NARROW

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML.

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Genetic Variants in the Candidate Genes of the Apoptosis Pathway and Susceptibility to Chronic Myeloid Leukemia

Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy.

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only